Mirati gets EC approval for Krazati to treat KRASG12C mutated NSCLC
EC has cleared Adagrasib as a targeted treatment option for adult patients with KRASG12C-mutated advanced NSCLC and disease…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Jan 24
EC has cleared Adagrasib as a targeted treatment option for adult patients with KRASG12C-mutated advanced NSCLC and disease…
10 Jan 24
The collaboration leverages NovaBay's extensive expertise in eye care, demonstrated by its Avenova brand, and Sonoma's ability to…
10 Jan 24
AbbVie has launched the solution to treat PD with severe motor fluctuations and hyperkinesia or dyskinesia, and when…
10 Jan 24
Under the agreement, Menarini will buy the exclusive rights to commercialise cefepime-taniborbactam in 96 countries in return for…
10 Jan 24
AR-15512, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment…
10 Jan 24
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
09 Jan 24
The acquisition will grant Merck access to Harpoon’s two immunotherapies in early-stage development, one for a type of…
09 Jan 24
The deal is expected to grant Novartis access to Cytokinetics' experimental treatment for hypertrophic cardiomyopathy treatment, Aficamten, which…
09 Jan 24
The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate…
08 Jan 24
In the trial, the vaccine demonstrated non-inferiority to Shingrix as measured by humoral immune response along with reduced…